1、项目类别及编号：主持1项国家自然科学基金青年科学基金项目 (No. 81001361)；名称：新型2,5,8-三取代二苯并呋喃及其NO供体偶联物的构建及抗AD活性研究；研究起止年月：2011.01-2013.12；资助金额：17万；进展情况：已结题。

2、项目类别及编号：主持博士点基金青年教师项目(No. 20100092120046)；名称：新型肝靶向醌甲基前体型姜黄素衍生物的构建及抗肿瘤活性研究；研究起止年月：2011.01-2013.12；资助金额：3.6万；进展情况：已结题。

3、项目类别及编号：主持江苏省自然科学基金面上项目(No. BK20151402)；名称：杂合交联型肿瘤靶向胶束给药系统的设计、合成及构效关系研究；研究起止年月：2015.07-2018.06；资助金额：10万；进展情况：已结题。

4、主持、参与多项药物合成工艺改进、杂质研究以及新产品开发多项产业课题。

2021

1.       LiuZ, Zhang B, Liu Q, Fang L*, Gou S*. Blood-Brain Barrier Permeable andNO-Releasing Multifunctional Nanoparticles for Alzheimer's Disease Treatment:Targeting NO/cGMP/CREB Signaling Pathways. JMed Chem, 2021, 64(18):13853-13872.

2020

2.       ZhaoJ, Zhang X, Fang L*, Gao C, Xu C*, Gou S*. Iridium(III) Complex-DerivedPolymeric Micelles with Low Dark Toxicity and Strong NIR Excitation forPhototherapy and Chemotherapy. Small,2020, 16: 2000363

3.       LiuZ, Wang M, Wang H, Fang L*, Gou S*. Platinum-Based Modification ofStyrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAFPathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance. J Med Chem, 2020, 63(1):186-204.

4.       LiuZ , WangM, WangH, FangL, GouS. TargetingRAS-RAF pathway significantly improves antitumor activity of Rigosertib-derivedplatinum(IV) complexes and overcomes cisplatin resistance. Eur J Med Chem, 2020, 194(1):112269. 

2019

5.       FangL, Qin X, Zhao J, Gou S*. Construction of Dual Stimuli-Responsive Platinum(IV)Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance. Inorg Chem, 2019, 58(3):2191-2200.

6.       SunC, Fang L, Zhang X, Gao P, Gou S*. Novel 7-formyl-naphthyridyl-ureasderivatives as potential selective FGFR4 inhibitors: Design, synthesis, andbiological activity studies. Bioorg MedChem, 2019, 27(10):1932-1941.

7.       SunC, Fang L, Gou S*. Discovery of a novel FGFR4 selective inhibitor via SARstudies of FGF401. Chinese Journal ofOrganic Chemistry, 2019, accept.

2018

8.       QinX, Fang L(房雷,并列第一作者), Zhao J, Gou S*. Theranostic Pt(IV)Conjugate with Target Selectivity for Androgen Receptor. Inorg Chem, 2018, 57(9):5019-5029.

9.       LiuY, Xia Q, Fang L(房雷,通讯作者). Design and synthesis of alkyl substitutedpyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improvedpharmacokinetic properties and potent in vivo antitumor activity. Bioorg Med Chem, 2018, 26(14):3992-4000.

2017

10.    Liu Z, FangL(房雷,通讯作者), Zhang H, Gou S, Chen L. Design, synthesisand biological evaluation of multifunctional tacrine-curcumin hybrids as newcholinesterase inhibitors with metal ions-chelating and neuroprotectiveproperty. Bioorg Med Chem, 2017, 25(8):2387-2398.

11.    Qin X, Fang L(房雷,并列第一作者), Chen F, Gou S*. Conjugation of platinum(IV) complexes withchlorambucil to overcome cisplatin resistance via a "joint action"mode toward DNA. Eur J Med Chem, 2017, 137:167-175.

12.    Qin X, Xu G, Chen F, Fang L(房雷,通讯作者), Gou S*. Novel platinum(IV) complexes conjugated with a wogoninderivative as multi-targeted anticancer agents. Bioorg Med Chem, 2017, 25(8):2507-2517.

2016

13.    Fang L(房雷),Feng M, Chen F, Liu X, Shen H, Zhao J, Gou S. Oleanolic acid-NOdonor-platinum(II) trihybrid molecules: Targeting cytotoxicity on hepatomacells with combined action mode and good safety. Bioorg Med Chem, 2016,24(19):4611-4619.

14.    Fang L(房雷),Chen M, Liu Z, Fang X, Gou S, Chen L. Ferulic acid-carbazole hybrid compounds:Combination of cholinesterase inhibition, antioxidant and neuroprotection asmultifunctional anti-Alzheimer agents. BioorgMed Chem, 2016, 24(4): 886-893.

15.    Wang Z, Yu H, Gou S, Chen F, Fang L(房雷,通讯作者). Design, Synthesis, and Biological Featuresof Platinum(II) Complexes with Rigid Steric Hindrance. Inorg Chem, 2016, 55(9):4519-4528.

16.    Yu H, Gou S, Wang Z, Chen F, Fang L(房雷,通讯作者). Toward overcoming cisplatin resistance via sterically hinderedplatinum(II) complexes. Eur J Med Chem,2016, 114:141-152.

17.    Lyu A, Qin X, Fang L(房雷,通讯作者),Gou S. Synthesis, cytotoxicity, and interaction with DNA of platinum(II)complexes of (1R,2R)N12amyl1,2diaminocyclohexane. J Coord Chem, 2016,69(10):1653–1662.

18.    Zhao J(并列第一作者), Fang L(房雷,并列第一作者), Zhang X, Liang Y, Gou S. Synthesis andbiological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives aspotential c-Met inhibitors. Bioorg MedChem, 2016, 24(16):3483-3493.

2015

19.    Liu F, Gou S, Chen F, Fang L(房雷,通讯作者),Zhao J. Study on Antitumor Platinum(II) Complexes of Chiral Diamines withDicyclic Species as Steric Hindrance. J Med Chem, 2015, 58(16): 6368-6377.

20.    LyuA(并列第一作者),Fang L(房雷,并列第一作者), Gou S,Liu X. Design, Synthesis and Biological Evaluation of Lapatinib Derivatives asHER1/HER2 Inhibitors. Lett Drug Des Discov,2015, 12(7):574­584.

2014

21.    Fang L(房雷), Wang M, Gou S, Liu X, Zhang H, CaoF. Combination of Amino Acid/Dipeptide with Nitric Oxide-donating OleanolicAcid Derivatives as PepT1 Targeting Antitumor Prodrugs. J Med Chem, 2014, 57(3):1116-1120.

22.    Fang L(房雷), Fang X, Gou S, Lupp A, LenhardtI, Sun Y, Huang Z, Chen Y, Cheng L, Zhang Y, Fleck C. Design, synthesis andbiological evaluation of D-ring opened galantamine analogs as multifunctionalanti-Alzheimer agents. Eur J Med Chem,2014, 76:376-386.

23.    Fang L(房雷),Gou S, Liu X, Cao F, Cheng L. Design, synthesis andanti-Alzheimer properties of dimethylaminomethyl-substituted curcuminderivatives. Bioorg Med Chem Lett, 2014, 24(1):40-43.

24.    Fang L(房雷),Zhang H, Fang X, Gou S, Cheng L. Preparation of carbazole and dibenzofuranderivatives by selective bromination on aromatic rings or benzylic groups withN-bromosuccinimide. Indian J Chem B,53(5): 635-641.

25.    LyuA(并列第一作者),Fang L(房雷,并列第一作者), Gou S. Designand synthesis of Lapatinib derivatives containing a branched side chain asHER1/HER2 targeting antitumor drug candidates. Eur J Med Chem, 2014,87:631-642.